BioVie Announces $4.74M Registered Direct Offering And Concurrent Private Placement

BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 2,962,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.60 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue and sell unregistered common warrants to purchase up to 2,962,500 shares of common stock (together with the registered direct offering, the "Offering"). The common warrants will have an exercise price of $1.70 per share, will be exercisable six months following their issuance and will expire five and a half years from the issuance date.

The gross proceeds from the Offering are expected to be approximately $4.74 million, before deducting placement agent commissions and other Offering expenses. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

The closing of the Offering is expected to occur on or about November 5, 2026, subject to the satisfaction of customary closing conditions.